Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy

Growth Hormone and IGF Research

Volumn 22, Issue 2, 2012, Pages 69-75

  Gehrig, Stefan M ^a   van der Poel, Chris ^a   Hoeflich, Andreas ^b   Naim, Timur ^a   Lynch, Gordon S ^a   Metzger, Friedrich ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b LEIBNIZ INSTITUTE FOR FARM ANIMAL BIOLOGY FBN   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Duchenne MD; IGF 1; Mouse models; PEGylated IGF 1

Indexed keywords

DYSTROPHIN; MACROGOL; PEGYLATED INSULIN LIKE GROWTH FACTOR I; RECOMBINANT SOMATOMEDIN C; UNCLASSIFIED DRUG; UTROPHIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAPHRAGM MUSCLE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; FATIGUE; MALE; MOUSE; MUSCLE CONTRACTION; MUSCLE INJURY; NEWBORN; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; SURVIVAL TIME; TIBIALIS ANTERIOR MUSCLE; TREATMENT DURATION;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DYSTROPHIN; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR I; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MICE, TRANSGENIC; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES; MUSCULAR DYSTROPHY, DUCHENNE; PHENOTYPE; POLYETHYLENE GLYCOLS; TIME FACTORS;

EID: 84859158181     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2012.02.004     Document Type: Article

References (29)

1. Acharyya S., Villalta S.A., Bakkar N., Bupha-Intr T., Janssen P.M., Carathers M., Li Z.W., et al. Interplay of IKK/NF-κB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J. Clin. Invest. 2007, 117:889-901.
2. Bani C., Lagrota-Candido J., Pinheiro D.F. Pattern of metalloprotease activity and myofiber regeneration in skeletal muscles of mdx mice. Muscle Nerve 2008, 37:583-592.
3. Hnia K., Gayraud J., Hugon G., et al. L-arginine decreases inflammation and modulates the nuclear factor-κB/matrix metalloproteinase cascade in mdx muscle fibers. Am. J. Pathol. 2008, 172:1509-1519.
4. Engel A.G., Yamamoto M., Fischbeck K.H. Dystrophinopathies. Myology 1994, 1133-1187. McGraw-Hill, New York. A.G. Engel, C. Franzini-Armstrong (Eds.).
5. Barton-Davis E.R., Shoturma D.I., Musaro A., Rosenthal N., Sweeney H.L. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:15603-15607.
6. Jacquemin V., Furling D., Bigot A., Butler-Browne G.S., Mouly V. IGF-1 induces human myotube hypertrophy by increasing cell recruitment. Exp. Cell Res. 2004, 299:148-158.
7. Zdanowicz M.M., Moyse J., Wingertzahn M.A., O'Connor M., Teichberg S., Slonim A.E. Effect of insulin-like growth factor I in murine muscular dystrophy. Endocrinology 1995, 136:4880-4886.
8. Wingertzahn M.A., Zdanowicz M.M., Slonim A.E. Insulin-like growth factor-I and high protein diet decrease calpain-mediated proteolysis in murine muscular dystrophy. Exp. Biol. Med. 1998, 218:244-250.
9. G.S. Lynch, Novel therapies for muscular dystrophy. Expert Opin. Therapeutic Patents 11 (2001) 587-601.
10. Festoff B.W. The preclinical rationale for the use of insulin-like growth factor-I in amyotrophic lateral sclerosis. Drugs Today 1998, 34:65-77.
11. Bulfield G., Siller W.G., Wight P.A.L., Moore K.J. X-chromosome linked muscular dystrophy (mdx) in the mouse. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:1189-1192.
12. Hoffman E.P., Brown R.J., Kunkel L.M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987, 51:919-928.
13. Granchelli J.A., Pollina C., Hudecki M.S. Pre-clinical screening of drugs using the mdx mouse. Neuromusc. Dis. 2000, 10:235-239.
14. Gregorevic P., Plant D.R., Leeding K.S., Bach L.A., Lynch G.S. Improved contractile function of the mdx dystrophic mouse diaphragm muscle following IGF-I administration. Am. J. Pathol. 2002, 161:2263-2272.
15. Gregorevic P., Plant D.R., Lynch G.S. Administration of insulin-like growth factor-I improves fatigue resistance of skeletal muscles from dystrophic mdx mice. Muscle Nerve 2004, 30:295-304.
16. Deconinck A.E., Rafael J.A., Skinner J.A., et al. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 1997, 90:717-727.
17. Metzger F., Sajid W., Saenger S., et al. Separation of fast from slow anabolism by site-specific PEGylation of insulin-like growth factor I. J. Biol. Chem. 2011, 286:19501-19510.
18. Saenger S., Goeldner C., Frey J.R., et al. PEGylation enhances the therapeutic potential for insulin-like growth factor I in central nervous system disorders. Growth Horm. IGF Res. 2011, 21:292-303.
19. S. Saenger, B. Holtmann, M.R. Nilges, et al., in press Functional improvement in mouse models of familial amyotrophic lateral sclerosis by PEGylated insulin-like growth factor I treatment depends on disease severity. Amyotroph. Lateral Scler.
20. Jablonka S., Holtmann B., Sendtner M., Metzger F. Therapeutic effects of PEGylated insulin-like growth factor I in the pmn mouse model of motoneuron disease. Exp. Neurol. 2011, 232:261-269.
21. Hoeflich A., Wu M., Mohan S., et al. Overexpression of insulin-like growth factor-binding protein-2 in transgenic mice reduces postnatal body weight gain. Endocrinology 1999, 140:5488-5496.
22. Gehrig S.M., Koopman R., Naim T., Tjoakarfa C., Lynch G.S. Making fast-twitch dystrophic muscles bigger protects them from contraction injury and attenuates the dystrophic pathology. Am. J. Pathol. 2010, 176:29-33.
23. Schertzer J.D., Ryall J.G., Lynch G.S. Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic mice. Am. J. Physiol. Endo. Metab. 2006, 291:E499-E505.
24. Musaro A., McCullagh K., Paul A., et al. Localized IGF-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nature Genet. 2001, 27:195-200.
25. Schertzer J.D., Lynch G.S. Comparative evaluation of IGF-I gene transfer and IGF-I protein administration for enhancing skeletal muscle regeneration and functional repair after injury. Gene Ther. 2006, 13:1657-1664.
26. Shavlakadze T., Chai J., Maley K., et al. A growth stimulus is needed for IGF-1 to induce skeletal muscle hypertrophy in vivo. J. Cell Sci. 2010, 123:960-971.
27. Lai E.C., Felice K.J., Festoff B.W., et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 1997, 49:1621-1630.
28. Borasio B.D., Robberecht W., Leigh P.N., et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 1998, 51:583-586.
29. Sorenson E.J., Windbank A.J., Mandrekar J.N., et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008, 71:1770-1775.